These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17802710)

  • 1. [Neuromuscular disorders due to adverse effects of antiparkinson agents].
    Hattori N
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1614-20. PubMed ID: 17802710
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
    Ahlskog JE
    Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
    Young BK; Camicioli R; Ganzini L
    Drugs Aging; 1997 May; 10(5):367-83. PubMed ID: 9143857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacotherapeutic treatment options in Parkinson's disease.
    Rezak M
    Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rasagiline for motor complications in Parkinson's disease.
    Clarke CE
    Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976
    [No Abstract]   [Full Text] [Related]  

  • 7. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
    Manca D; Cossu G; Murgia D; Molari A; Ferrigno P; Marcia E; Melis M
    Mov Disord; 2009 Nov; 24(15):2293-4. PubMed ID: 19795477
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy for patients with early-stage Parkinson's disease].
    Tanaka M; Okamoto K
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1426-31. PubMed ID: 13677890
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
    van Laar T; Lammers GJ; Roos RA; Gerritsen JJ; Meinders AE
    Mov Disord; 1998 Jan; 13(1):176-8. PubMed ID: 9452348
    [No Abstract]   [Full Text] [Related]  

  • 11. Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
    Nyholm D; Askmark H; Aquilonius SM
    Ann Neurol; 2011 Feb; 69(2):424; author reply 425. PubMed ID: 21387388
    [No Abstract]   [Full Text] [Related]  

  • 12. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
    Wilson L; Sheehan J; Thorpe M
    Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
    Klos KJ; Bower JH; Josephs KA; Matsumoto JY; Ahlskog JE
    Parkinsonism Relat Disord; 2005 Sep; 11(6):381-6. PubMed ID: 16109498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of Parkinson's disease].
    Baumann CR; Waldvogel D
    Praxis (Bern 1994); 2013 Dec; 102(25):1529-35. PubMed ID: 24326048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical treatment of L-dopa induced dyskinesia].
    Kuno S
    Nihon Rinsho; 2000 Oct; 58(10):2110-4. PubMed ID: 11068456
    [No Abstract]   [Full Text] [Related]  

  • 18. [Wearing-off phenomenon--neurological approach].
    Ishikawa A
    Nihon Rinsho; 2000 Oct; 58(10):2100-3. PubMed ID: 11068454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of rasagiline in elderly patients with Parkinson disease.
    Goetz CG; Schwid SR; Eberly SW; Oakes D; Shoulson I;
    Neurology; 2006 May; 66(9):1427-9. PubMed ID: 16682679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.